Aliases:This biomarker is also known as:
- free prostate-specific antigen (PSA) isoform,
ProPSA (-2), or [-2]proPSA, is a PSA isoform which has a leader peptide (-2) amino acids at its N terminal region and does not interact with ACT or alpha-2-macroglobulin or spermidine and therefore is detected as a separate isoform. ProPSA is produced primarily in the peripheral zone of the prostate gland and therefore is very useful in distinguishing between prostate cancer patients with PSA range of 2-10, from those who have BPH. Percent proPSA is the ratio of proPSA to free PSA. In July 2012 the FDA approved an assay measuring levels of [-2]proPSA for monitoring and diagnostic purposes.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
The measurement of PSA, free PSA, and pro-PSA can help a patient determine whether to undergo biopsy if his PSA level is between 4 and 10 ng/mL.
In July 2012 the FDA approved an assay measuring levels of [-2]proPSA, a form of pro-PSA, for monitoring and diagnostic purposes.
- Multi-center analytical performance evaluation of the Access HybritechÃƒÆ'Ã¢â‚¬Å¡Ãƒâ€šÃ‚Â® p2PSA immunoassay.
- From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer.
- A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness.
- 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY
- Draft Directional Insert
- FDA Medical Device description of Hybritech p2PSA assay
- Genecards record for human kallikrein 3, also known as PSA
- NCBI Gene entry for human KLK3
- NCI Fact Sheet for Prostate-Specific Antigen (PSA) Test
- National Cancer Institute News Note
- Summary of Safety and Effectiveness Data (SSED)